Medically reviewed by Edward Tavel, MD, Medical Director · Last reviewed 10 September 2026
If you are in your thirties or forties and have looked into multi-cancer early detection blood tests, you have probably run into the same wall: the age requirement. These tests are offered to adults 50 and older, and if you are younger, the answer is generally no.
That surprises people, particularly people who have read headlines about cancer rising in younger adults. This entry explains why the age indication exists, what the research on under-50 cancer actually shows — which is more specific and less alarming than the coverage suggests — and what screening options are genuinely available before 50.
Why the age indication exists
Both widely available multi-cancer early detection tests, often shortened to MCED tests, are written for older adults. Cancerguard from Exact Sciences is indicated for ages 50 through 84 in people who have not had a cancer diagnosis in the past three years. Galleri from GRAIL is indicated for adults with elevated risk, described as “such as age 50 or older,” with no upper limit, and requires a prescription.
The reason is arithmetic, not oversight. Cancer becomes considerably more common with age, so in an older group a given number of positive results is more likely to represent real disease. In a younger group, where cancer is rarer, the same test produces a higher proportion of false alarms relative to true findings. Since a positive MCED result typically leads to a series of imaging studies and sometimes a biopsy, running the test in a low-incidence population means more people going through that pathway without cancer at the end of it. Neither test is FDA-approved, the U.S. Preventive Services Task Force has issued no recommendation on either, and neither has been shown to reduce cancer deaths.
What the under-50 data actually shows
Here is where the public conversation and the published research part ways.
A 2025 National Cancer Institute analysis in Cancer Discovery examined U.S. cancer incidence from 2010 to 2019 across three younger age bands: 15–29, 30–39 and 40–49. Fourteen cancer types showed a significant increase in at least one of those groups. Nineteen types decreased. And the total rate of all cancers combined in adults under 50 did not increase.
That last finding is the one that rarely makes it into headlines, and it matters. There is no across-the-board surge in young-adult cancer. What exists is a specific pattern in specific cancers. Comparing 2019 diagnoses against 2010 rates, the excess was concentrated in four types: female breast cancer accounted for roughly 4,800 additional cases, colorectal cancer about 2,000, kidney cancer about 1,800 and uterine cancer about 1,200. Together those four represented more than 80% of the additional diagnoses. Of the fourteen rising types, four also showed rising death rates: testicular, uterine, colorectal, and bone and joint cancers.
So the accurate summary is narrow: several specific cancers are becoming more common in younger adults, the overall rate is not, and the specific cancers involved are worth paying attention to.
What is recommended under 50
More than most people realize.
Colorectal cancer screening now begins at age 45 for people at average risk — a change made directly in response to the rising incidence in younger adults. Cervical screening starts in the twenties. Mammography discussions typically begin around 40, and earlier for women with a family history or known genetic risk. Anyone with an inherited cancer predisposition syndrome, a strong family history, or a prior cancer diagnosis may qualify for surveillance programs that begin much earlier and are far more intensive than anything offered to the general population.
If you are under 50 and concerned, the highest-value conversation is usually about family history. It is the single factor most likely to change what your physician recommends, and it is often the one nobody has asked you about.
What imaging offers
Whole-body MRI is available to adults 18 and older, which makes it one of the few proactive screening options with no upper age gate and no lower one either. It works differently from a blood test: rather than looking for a chemical signal, it produces detailed images of internal structures, and our board-certified radiologists review them for anything abnormal in size, shape or texture. It uses no ionizing radiation, and our protocols use no contrast dye.
This is not a stand-in for a multi-cancer blood test. It asks a different question, and it is not a reason to skip the screening your age and family history already call for.
For a younger adult, the practical value is often the baseline. A scan in your thirties gives future scans something to be compared against, and change over time is frequently more informative than any single image.
The honest limits
A whole-body MRI is not a complete cancer screen, and we would rather say so plainly. Published studies of whole-body MRI in people without symptoms find confirmed cancer in roughly 1% to 2% of those scanned — a pooled figure of 1.57% across 9,024 participants in a 2025 European Radiology meta-analysis. Incidental findings, meaning spots and cysts that turn out to be harmless, have been reported in up to 97% of scans, and some of those lead to follow-up testing that finds nothing wrong.
MRI is also poor at detecting small lung nodules, does not evaluate the lining of the colon, and does not characterize thyroid nodules. A whole-body protocol is not the same as a dedicated breast or prostate MRI. It supplements guideline-based screening; it does not replace it. And there is no published evidence yet that whole-body MRI screening extends life — that research does not exist for any screening MRI protocol or any MCED test.
If you are under 50 and want to understand what different tools can and cannot see, our overview of cancer blood tests and whole-body MRI covers the comparison in more depth. And if you would like to talk through whether imaging fits your situation, our team is glad to have that conversation without any pressure to book.
Frequently asked questions
What is the age requirement for a multi-cancer early detection test?
Cancerguard is indicated for adults aged 50 to 84 with no cancer diagnosis in the past three years. Galleri is indicated for adults at elevated risk, described as age 50 or older, with no upper age limit, and requires a prescription. Neither test is FDA-approved, and neither is generally covered by insurance.
Is cancer really rising in young people?
Not overall. A 2025 National Cancer Institute analysis found that from 2010 to 2019, fourteen cancer types increased in at least one under-50 age group while nineteen decreased, and the combined rate of all cancers in adults under 50 did not increase. The rise is concentrated in specific cancers, chiefly female breast, colorectal, kidney and uterine.
What cancer screening is available if I am under 50?
Colorectal screening now begins at 45, cervical screening begins in the twenties, and mammography discussions typically begin around 40 or earlier with family history. People with inherited cancer risk may qualify for surveillance starting much earlier. Family history is the factor most likely to change what your doctor recommends.
Can I get a whole-body MRI before age 50?
Yes. MRI Wellness scans adults 18 and older. A scan does not replace mammography, colonoscopy, cervical screening or low-dose CT, and confirmed cancer is found in roughly 1% to 2% of asymptomatic people scanned. For younger adults, the main value is often establishing a baseline for future comparison.
Sources
- Trends in Cancer Incidence and Mortality Rates in Early-Onset and Older-Onset Age Groups in the United States, 2010-2019
- Cancer statistics, 2026
- Cancer Facts & Figures 2026
- Important Information about the Cancerguard® Test (Indications for Use)
- Frequently Asked Questions (FAQs) for Patients
- Frequently Asked Questions (FAQs) for Providers
- Safety Information
- Colorectal Cancer: Screening (Final Recommendation Statement)
- Questions and Answers about Multi-Cancer Detection Tests
- Whole-body MRI for opportunistic cancer detection in asymptomatic individuals: a systematic review and meta-analysis
A whole-body MRI at MRI Wellness looks at the brain, spine, chest, abdomen and pelvis in a single session, without radiation or contrast dye. No referral is needed.
